Skip to main content

TTX-030 in Combination With Immunotherapy and / or Chemotherapy in Subjects With Advanced Cancers

Trial Status: Active

This is a phase 1 / 1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and / or standard chemotherapies.

Inclusion Criteria

  • Age 18 years or older, is willing and able to provide informed consent
  • Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types
  • Life expectancy > 12 weeks
  • ECOG performance status of 0-1

Exclusion Criteria

  • History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
  • Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
  • Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
  • History of severe autoimmune disease
  • Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment

California

Duarte
City of Hope Comprehensive Cancer Center
Status: IN_REVIEW
Los Angeles
Los Angeles County-USC Medical Center
Status: ACTIVE
Contact: Xiomara Menendez
Phone: 323-865-0212
UCLA / Jonsson Comprehensive Cancer Center
Status: ACTIVE
Contact: Lisa Yonemoto
Phone: 310-825-4477
USC / Norris Comprehensive Cancer Center
Status: ACTIVE
Contact: Xiomara Menendez
Phone: 323-865-0212
Newport Beach
Hoag Memorial Hospital
Status: ACTIVE
Contact: Xiomara Menendez
Phone: 323-865-0212
Orange
UC Irvine Health / Chao Family Comprehensive Cancer Center
Status: ACTIVE
Sacramento
University of California Davis Comprehensive Cancer Center
Status: ACTIVE

Florida

Miami
University of Miami Miller School of Medicine-Sylvester Cancer Center
Status: ACTIVE

Illinois

Chicago
University of Chicago Comprehensive Cancer Center
Status: ACTIVE

New Hampshire

Lebanon
Dartmouth Hitchcock Medical Center
Status: APPROVED

New York

Bronx
Montefiore Medical Center-Weiler Hospital
Status: ACTIVE

Ohio

Cleveland
Case Comprehensive Cancer Center
Status: ACTIVE

Pennsylvania

Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: ACTIVE

Utah

Salt Lake City
Huntsman Cancer Institute / University of Utah
Status: ACTIVE

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Trishula Therapeutics, Inc.

  • Primary ID TTX-030-002
  • Secondary IDs NCI-2020-02350
  • Clinicaltrials.gov ID NCT04306900